Mark brings over 30 years of finance experience spanning emerging biotech, large pharma, and Wall Street.   He was most recently the CFO at Vedanta Biosciences where he was instrumental in raising approximately $200M through multiple financing rounds.  He prepared the company for IPO including implementing the financial controls, IT systems, and processes, as well as preparing and filing the IPO prospectus with the SEC and conducting test-the-waters meetings with investors.  Prior to Vedanta, he was VP of Finance & Investor Relations at Editas Medicine where he built the investor relations function and raised approximately $700M from IPO through multiple rounds of public offerings. Earlier in his career, he held finance and corporate development leadership roles at Novartis and led IPOs as an equity research analyst at Piper Sandler. He started his career in the finance and strategy consulting practice at Deloitte.       

Mark earned his BA in Economics from the University of Chicago with Phi Beta Kappa honors and MBA in Finance and Accounting from the MIT Sloan School of Management.